Quest Magazine

DMD: Eteplirsen-Treated Boys Show Continued Stability at 120 Weeks

Boys with Duchenne muscular dystrophy (DMD) participating in a phase 2b extension trial of the experimental exon-skipping drug eteplirsen showed continued stabilization of walking distance at 120 weeks. Sarepta Therapeutics, developer of eteplirsen, announced the findings in a Jan. 15, 2014, press release.

Paintings by Minnesota Artist Accepted into MDA Art Collection

DMD: GSK Returns Drisapersen Development Rights to Prosensa

The rights to development of the experimental Duchenne muscular dystrophy (DMD) drisapersen have now been returned to the drug's original developer, Dutch biotechnology company Prosensa. The rights were formerly jointly held by Prosensa and multinational pharmaceutical company GlaxoSmithKline (GSK).

College Course on DMD Available Online

A course on Duchenne muscular dystrophy (DMD), geared toward graduate and upper-division undergraduate students and held at Ohio State University College of Medicine and Nationwide Children's Hospital in Columbus, is open to the public, without charge, via real-time streaming and podcasts.

HT-100 Clinical Program Status Changed

International ALS Symposium Stresses Progress

"We are undoubtedly slowing down the MND [motor neuron disease] supertanker, and can start to see how we might turn it around for the first tim," said Martin Turner, senior clinician scientist at the University of Oxford (United Kingdom), on research being reported on at the 24th International Symposium on ALS/MND.

New Nationwide MDA Endurance Program Off and Running

Immune System Modulator in Development for ALS

Trial of Tadalafil in DMD Open to Participants

DMD/BMD: Stop Codon Read-Through Drug Trial Still Recruiting Participants

Pages